Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry.
The inclusion of protease inhibitors in serum or plasma samples has been found to significantly impact the isoform profile of selected plasma proteins as seen on 2-dimensional electrophoresis (2-DE) gels. With the addition of a protease inhibitor cocktail, several human plasma protein trains [depleted of albumin and immunoglobulin G (IgG)] exhibited higher isoelectric point (pI) isoforms. This shift was especially apparent for apolipoprotein A1 (apo A1), a relatively high abundance protein. The six protease inhibitor components of the cocktail were individually investigated with albumin and IgG depleted human plasma, and it was shown that the observed effects were caused by 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), a serine protease inhibitor that covalently modifies proteins and/or peptides. Several serine-and/or tyrosine-containing peptides of apo A1 were modified with a concomitant mass increase of 183 Da, which is consistent with the mass increase expected following reaction with AEBSF. These modifications were observed with increasing propensity in the higher pI spots. An increase in both the number and proportion of modified peptides with increasing pI was also observed. A model is proposed for the random or stochastic coupling of AEBSF-derived moieties to serine and/or tyrosine residues throughout apo A1 and potentially other plasma proteins.
Schuchard
Mark D
MD
Sigma-Aldrich Biotechnology, St. Louis, MO 63178, USA.
Mehigh
Richard J
RJ
Cockrill
Steven L
SL
Lipscomb
George T
GT
Stephan
Jonathan D
JD
Wildsmith
Justin
J
Valdes-Camin
Rafael
R
Kappel
William K
WK
Rai
Alex J
AJ
Scott
Graham B I
GB
D016477:Artifacts; D001774:Blood Chemical Analysis / Q000379:methods*; D001798:Blood Proteins / Q000032:analysis* / Q000737:chemistry*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D020869:Gene Expression Profiling / Q000379:methods*; D013058:Mass Spectrometry / Q000379:methods*; D010949:Plasma / Q000737:chemistry; D011480:Protease Inhibitors / Q000737:chemistry*; D020033:Protein Isoforms / Q000032:analysis / Q000737:chemistry; D044967:Serum / Q000737:chemistry; D013048:Specimen Handling / Q000379:methods
D001798:Blood Proteins; D011480:Protease Inhibitors; D020033:Protein Isoforms